COMMERCIALIZING WORLD-CLASS CANCER INNOVATION

Seeding and scaling Ontario’s premiere entrepreneurial ventures for patients and the economy.

ONTARIO RESEARCH Leveraging breakthrough innovation and community network COMMERCIALIZATION VENTURE Investing seed capital, creating & scaling start-ups, securing strategic partners PATIENT & ECONOMIC IMPACT Driving clinical trials, job creation, talent development, sustainable biotech in Ontario ONTARIO RESEARCH Leveraging breakthrough innovation and community network COMMERCIALIZATION VENTURE Investing seed capital, creating & scaling start-ups, securing strategic partners PATIENT & ECONOMIC IMPACT Driving clinical trials, job creation, talent development, sustainable biotech in Ontario

OUR IMPACT

Increasing the value of Ontario’s best oncology innovations and attracting investment from the private sector

invested

additional financing attracted

Ontario start-ups created

first-in-human studies

PORTFOLIO

Our investments are at the forefront of Ontario’s biotech ecosystem.

FIND OUT MORE

FUNDS

Our investments bridge the life sciences seed funding gap.

FIND OUT MORE


KEY SUCCESSES

Our investments have resulted in significant partnerships, clinical trials, job creation and leveraged financing for the province.


RECENT NEWS

Keep up to date on our investments and business developments in recent news stories and summaries.

  • Newsweek: The New Era of Life Sciences 2024

    May 15, 2024 – FACIT President discusses early-stage investing in Canada in an interview with Newsweek’s Investment Reports and appeared in The New Era of Life Sciences 2024. FACIT is an innovative organization focused on bridging the gap between cancer research breakthroughs and their commercialization, thereby accelerating the journey of scientific discoveries from the laboratory…

    Read More

  • Cutting-edge radiosurgery tech for brain tumours wins 2024 Falcons’ Fortunes

    May 6, 2024 – At the sold-out Falcons’ Fortunes pitch competition hosted by FACIT, Dr. Hatim Fakir delivered the winning pitch as selected by the panel of judges for the $100,000 Ernsting Entrepreneurship Award. Developed at London Health Sciences Centre, Dr. Fakir’s RadioSphere is a patient-centred technology to revolutionize existing gamma knife radiotherapy procedures by…

    Read More

  • FACIT-seeded Fusion Pharmaceuticals acquired for up to US$2.4B by AstraZeneca

    March 20, 2024 – FACIT’s portfolio company Fusion Pharmaceuticals is being acquired by AstraZeneca for a total transaction value of up to $2.4 billion. Congratulations to the team at Fusion for building value over the last decade that will have a lasting impact on patients with cancer and the Ontario economy. Read More from FACIT-seeded…

    Read More

We were established by the Ontario Institute for Cancer Research (OICR) to support commercialization, technology transfer, and development activities. OICR conducts and enables world-class cancer research, filling a critical role as a pan-provincial connector of oncology researchers, resources and cancer innovation development. Together with OICR, we drive a shared vision to attract more R&D investment in Ontario and help the best oncology innovations reach the market and save lives. 

FACIT is funded in part by the Government of Ontario through OICR